Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 99 results for pulmonary hypertension

  1. Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)

    Evidence-based recommendations on bevacizumab (Avastin), with other drugs, for treating metastatic colorectal cancer in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA212

  2. Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)

    Evidence-based recommendations on sunitinib (Sutent) for treating gastrointestinal stromal tumours in adults.

    Technology appraisal guidance
    Published
    23 September 2009
    View recommendations

    Sections for TA179

  3. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    26 August 2009
    View recommendations

    Sections for TA178

  4. Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (HTG175)

    Evidence-based recommendations on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. This involves removing parts of the pancreas (islet cells) after the pancreas has been removed and inserting them into the liver to restart insulin production.

    HealthTech guidance
    Published
    24 September 2008
    View recommendations

    Sections for HTG175

  5. Hybrid procedure for interim management of hypoplastic left heart syndrome in neonates (HTG158)

    Evidence-based recommendations on hybrid procedure for interim management of hypoplastic left heart syndrome in neonates. This involves placing bands around the branches of the pulmonary artery and inserting stents to keep the ductus arteriosus open.

    HealthTech guidance
    Published
    12 December 2007
    View recommendations

    Sections for HTG158

  6. Therapeutic amnioinfusion for oligohydramnios during pregnancy (excluding labour) (HTG124)

    Evidence-based recommendations on therapeutic amnioinfusion for treating oligohydramnios during pregnancy (excluding labour). This involves injecting a substance similar to amniotic fluid into the space around the baby.

    HealthTech guidance
    Published
    22 November 2006
    View recommendations

    Sections for HTG124

  7. Living-donor lung transplantation for end-stage lung disease (HTG111)

    Evidence-based recommendations on living-donor lung transplantation for end-stage lung disease. This involves removing a lung from each of the two donors and replacing the recipient's lungs with the donor lungs.

    HealthTech guidance
    Published
    24 May 2006
    View recommendations

    Sections for HTG111

  8. Balloon dilatation of systemic to pulmonary arterial shunts in children (HTG48)

    Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.

    HealthTech guidance
    Published
    28 July 2004
    View recommendations

    Sections for HTG48

  9. Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Drugs for the treatment of pulmonary arterial hypertension [ID12]

    Discontinued Reference number: GID-TAG382

    Technology appraisal guidance
    Discontinued

  11. Cardiometabolic disease prevention and treatment guidelines

    aortic valve implantation (TAVI) to treat aortic stenosis Hypertension in adults: diagnosis and management - Non-alcoholic fatty

    NICE guideline
    In development

  12. Obicetrapib and obicetrapib–ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia ID6519

    In development Reference number: GID-TA11649 Expected publication date:  14 October 2026

    Technology appraisal guidance
    In development

  13. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  14. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development Reference number: GID-TA11103 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Macitentan for treating pulmonary arterial hypertension in people 1 month to 17 years [TSID11805]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation